$
35.190
-0.73(-2.032%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
36.580
Open
36.390
VWAP
35.35
Vol
992.36K
Mkt Cap
1.27B
Low
34.800
Amount
35.08M
EV/EBITDA(TTM)
--
Total Shares
35.97M
EV
591.32M
EV/OCF(TTM)
--
P/S(TTM)
8.81
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Show More
2 Analyst Rating
up Image
15.09% Upside
Wall Street analysts forecast GRAL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRAL is 40.50 USD with a low forecast of 38.00 USD and a high forecast of 43.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
up Image
15.09% Upside
Current: 35.190
sliders
Low
38.00
Averages
40.50
High
43.00
Morgan Stanley
Equal Weight
initiated
$20 -> $38
2025-06-26
Reason
Morgan Stanley assumed coverage of Grail with an Equal Weight rating and a price target of $38, up from $20. While the firm sees significant long-term potential for Grail's Galleri MCED test, there are also inherent risks associated with novel technologies from a regulatory and reimbursement standpoint, the analyst tells investors. The firm is also updating estimates for Q1 results, noting that its Q2 and 2025 revenue estimates move to $36M and $151M, from prior forecasts of $37M and $149M, respectively.
NINGI Research
NINGI Research
downgrade
$14.28
2025-06-09
Reason
Canaccord
Buy
maintain
$32 -> $43
2025-05-14
Reason
Canaccord Genuity
Kyle Mikson
Strong Buy
Initiates
$32
2025-04-21
Reason
Morgan Stanley
Tejas Savant
Hold
Maintains
$16 → $20
2025-03-18
Reason
Morgan Stanley
Tejas Savant
Hold
Initiates
$16
2024-11-27
Reason
Morgan Stanley initiated coverage of Grail with an Equal Weight rating and $16 price target. The company's Galleri multi-cancer early detection screening test has the potential to address a significant unmet need, the analyst tells investors in a research note. The firm says that while Grail's cash preservation efforts are encouraging, with Medicare reimbursement, the key catalyst to unlocking share value, essentially a 2027 dynamic, the stock's near-term risk/reward is balanced.

Valuation Metrics

The current forward P/E ratio for Grail Inc (GRAL.O) is -2.42, compared to its 5-year average forward P/E of -1.24. For a more detailed relative valuation and DCF analysis to assess Grail Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.24
Current PE
-2.42
Overvalued PE
-0.14
Undervalued PE
-2.35

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.62
Current EV/EBITDA
-1.87
Overvalued EV/EBITDA
0.38
Undervalued EV/EBITDA
-1.62

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PS
4.56
Current PS
8.53
Overvalued PS
8.28
Undervalued PS
0.83

Financials

Annual
Quarterly
FY2025Q1
YoY :
+19.15%
31.84M
Total Revenue
FY2025Q1
YoY :
-32.44%
-153.64M
Operating Profit
FY2025Q1
YoY :
-51.48%
-106.21M
Net Income after Tax
FY2025Q1
YoY :
-62.42%
-3.10
EPS - Diluted
FY2025Q1
YoY :
-54.69%
-95.07M
Free Cash Flow
FY2025Q1
YoY :
-23.65%
-62.60
Gross Profit Margin - %
FY2025Q1
YoY :
-44.43%
-357.74
FCF Margin - %
FY2025Q1
YoY :
-59.28%
-333.61
Net Margin - %

Trading Trends

Insider
Insiders areSelling! The selling amount has increased 3301.22% over the last month.
Sold
0-3
Months
23.9M
USD
6
3-6
Months
360.4K
USD
3
6-9
Months
0.0
USD
0
0-12
Months
3.2M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
4
1.0M
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
410.2K
Volume
1
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
12.5K
Volume
Months
6-9
1
1.6M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

GRAL News & Events

Events Timeline

2025-06-27 (ET)
2025-06-27
10:44:35
Supreme Court keeps element of Obamacare preventive care, Reuters reports
select
link
2025-06-18 (ET)
2025-06-18
09:03:52
Grail reports results from PATHFINDER 2 study
select
2025-05-13 (ET)
2025-05-13
16:03:39
Grail reports Q1 EPS ($3.10), consensus ($3.80)
select
Sign Up For More Events

News

5.0
06-20Newsfilter
With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
4.5
06-18Benzinga
Wall Street Rises Ahead Of Fed, Payment Stocks Fall On Stablecoin Bill: What's Driving Markets Wednesday?
9.0
06-18Newsfilter
GRAIL Announces Positive Top-Line Results From The Galleri® PATHFINDER 2 Registrational Study
Sign Up For More News

FAQ

arrow icon

What is Grail Inc (GRAL) stock price today?

The current price of GRAL is 35.19 USD — it has decreased -2.03 % in the last trading day.

arrow icon

What is Grail Inc (GRAL)'s business?

arrow icon

What is the price predicton of GRAL Stock?

arrow icon

What is Grail Inc (GRAL)'s revenue for the last quarter?

arrow icon

What is Grail Inc (GRAL)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Grail Inc (GRAL)'s fundamentals?

arrow icon

How many employees does Grail Inc (GRAL). have?

arrow icon

What is Grail Inc (GRAL) market cap?